The molecular landscape of PIWIL1 expression in colorectal adenocarcinoma (CRC).




¹ Hackensack University Medical Center, Hackensack, NJ;² Caris Life Sciences, Phoenix, AZ;³ University of Minneapolis, MN; Department of Clinical Oncology, ⁵St. Marianna University School of Medicine, Kawasaki, Japan; ³Barbara Ann Karmanos Cancer Institute, Detroit, MI; Washington University in St. Louis, Siteman Cancer Center, St. Louis, MO; Norris Comprehensive Cancer Center, Keck School of Medicing, University of Southern California, Los Angeles, CA; Levine Cancer Institute, Charlotte, NC; West Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Morgantown, WV; Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC

BACKGROUND

PRECISION ONCOLOGY

ALLIANCE

PIWIL1 is a cancer testis antigen overexpressed in solid tumors, particularly CRC, and is associated with advanced stage and poor prognosis. It is potentially a new therapeutic target, as PIWIL1 is not expressed in adult somatic tissue. A novel T cell receptor/PIWIL1 bispecific antibody is in development and restricted to individuals with human leukocyte antigen (HLA) A-02. We sought to characterize the molecular landscape of PIWIL1 in CRC.



METHODS

26,581 CRC tumors were tested by next-generation sequencing (NGS) on DNA (592-gene or whole exome [WES]) and RNA (whole transcriptome [WTS]) at Caris Life Sciences (Phoenix, AZ). dMMR/MSI-H was tested by immunohistochemistry (IHC) and NGS respectively, HLA genotypes by WES and PD-L1 by IHC (SP142, 2+, 5% which was the threshold used for positivity). Tumor mutational burden (TMB) high was defined as \geq 10 mt/Mb. RNA expression was used to estimate the tumor microenvironment using QuantiSEQ; T-cell inflamed score [TIS]) was used to predict immune checkpoint blockade (IO) response. The top (H) and bottom (L) quartiles of *PIWIL1* expression were compared using Chi-square/Fisher-Exact, and significance was determined as p adjusted for multiple comparisons (Q<0.05). Real-world overall survival (rwOS) was obtained from insurance claims and calculated from tissue collection to last contact.

CONCLUSION


PIWIL1-H CRC is associated with higher rates of dMMR/MSI-H, TMB-H and PD-L1+ as well as IO-related gene expression and signatures that are predictive of response to IO. These data suggest the PIWIL1-H subpopulation could potentially derive substantial benefit from PIWIL1-targeted immunotherapy which should be evaluated in clinical trials.

Tony Varughese¹, Yasmine Baca,²Lishann Ingram,²Gretchen Hubbard,²Joanne Xiu,²Emil Lou,³ Hiroyuki Arai,⁴Anthony F. Shields, ⁵Moh'd M. Khushman, Francesca Battaglin, Jimmy J. Hwang, Richard M. Goldberg, Andreas Seeber, Heinz-Josef Lenz, Sanjay Goel, John Marshall, 12 Matthew James Oberley, Benjamin A. Weinberg

RESULTS

Parameter	PIWIL1-H	PIWIL1-L
Sample Size	n=6645	n=6646
Median Age	65*	61
Gender (% female)	50.8%*	41.3%
<u>ନ୍ଥ</u> TP53	81%*	69 %
KRAS	53%*	41%
BRAF	16%*	3%
TP53 KRAS BRAF PIK3CA	14%	17%*
Genomic Loss of Heterozygosity	14%*	10%

Table 1: Patient Characteristics






Figure 2: IO Marker Association: MSI-H, TMB-H and PD-L1-H were all positively associated with *PIWIL1* expression.





Figure 4: MAPK pathway activity score, T cell inflamed score, and IFN were all positively associated with *PIWIL1* expression. (p value, q value < 0.001)



monocytes, CD4+T, dendritic and NK cells (FC: 1.3-2.9, Q<0.05) while Tregs and M1 macrophages had a negative association (0.8-0.9, Q<0.05).





Hackensack Meridian John Theurer Cancer Center

Consortium Member of Georgetown Lombardi COMPREHENSIVE CANCER CENTER



% PIWIL1-H 8 %PIWIL1-L % PIWIL1-H 📃 % PIWIL1-L 81.29 NGS-TP53 69.1% 52.6% NGS-KRAS 41.1% 17.6 NGS-BRAF NGS-PIKC3A 10.2% Within NGS-LOH DMMR/MSS all q<0.05 Figure 3: *PIWIL1*-H associated with higher rates of gene expression of KRAS, BRAF, PIKC3A, and LOH